Paper Review Records
All Paper Review Records
15 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
65
days
Twenty-five years survival of primary central nervous system lymphomas treated with the C5R regimen
Authors
Jean-Yves Blay; Sylvain Lamure; Waisse Waissi; Marie-Pierre Sunyach; Haifa Bahri; Philippe Rey; Catherine Chassagne-Clement; Emmanuelle Nicolas-Virelizier; Amine Belhabri; Yann Guillermin; Pierre Biron; Catherine Sebban; Thierry Philip; Claire Cropet; Hervé Ghesquieres; Anne-Sophie MichalletShow moreShow less
Affiliations
Centre Léon Bérard, 28, rue Laennec, Lyon 69008, France; Service d’Hématologie, CHLS, Pierre-Bénite, FranceShow moreShow less
95
days
Diagnostic pitfalls and unmet needs in neuroendocrine neoplasms: The added value of collegial expert pathology review through the national TENpath network
Authors
Matthieu Tihy; Jean-Yves Scoazec; Serge Guyétant; Mohamed-Amine Bani; Céline Bazille; Geneviève Belleannée; Christian Boissy; Camille Boulagnon-Rombi; Aurélie Cazes; Aurélie Charissoux; Marie-Pierrette Chenard; Marie Danjoux; Camille Darcha; Laurent Doucet; Charlotte Dufour; Antonin Fattori; Anne Guyot; Valérie Hervieu; Marie-Françoise Heymann; Catherine Julié; Thibault Kervarrec; Cosmin Lazaroiu; Emmanuelle Leteurtre; Laurent Martin; Stéphanie Patouraux; Flora Poizat; Nicolas Poté; Agathe Régnier; Benjamin Rivière; Magali Svrcek; Benoît Terris; Jérôme Cros; Anne CouvelardShow moreShow less
Affiliations
Université Paris-Cité, Service d′Anatomie Pathologique, ENETS Center of Excellence, Hôpital Bichat (AP-HP), Paris, France; Service de Pathologie, Gustave Roussy Cancer Center, Villejuif, France; Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France; Service d′anatomie pathologique et Plateforme de génétique moléculaire des cancers, Hôpital Trousseau, CHRU, UMR INRAE ISP 1282, université de Tours, Tours, France; Service d’Anatomie Pathologique, CHU, Caen, France; Service d’Anatomie Pathologique, CHU, Bordeaux, France; Laboratoire Central d′Anatomie et de Cytologie Pathologiques, Hôpital Pasteur, CHU, Nice, Université Côte d′Azur, Nice, France; Laboratoire de Pathologie, CHU, Reims, France; Service d’Anatomie Pathologique, CHU, Limoges, France; Service d’Anatomie Pathologique, CHU, Strasbourg, France; Service d’Anatomie Pathologique, Oncopole, Toulouse, France; Service d′Anatomie et Cytologie Pathologiques, CHU, Clermont-Ferrand, France; Service d’Anatomie Pathologique, Hôpital Morvan, CHRU, Brest, France; Service d’Anatomie Pathologique, CHU, Lille, France; Service d’Anatomie Pathologique, ENETS Center of Excellence, GHU Est, Hospices Civils de Lyon, Lyon, France; Institut de Cancérologie de l’Ouest, Département de Pathologie Tissulaire et Moléculaire, Saint-Herblain, France; Service d’Anatomie Pathologique, Hôpital Ambroise Paré (AP-HP), Boulogne-Billancourt, France; Service d’Anatomie Pathologique, CHU, Dijon, France; Service d’Anatomie Pathologique, ENETS Center of Excellence, IPC NET Center, Institut Paoli-Calmettes, Marseille, France; Service d’Anatomie Pathologique, CHU, Rouen, France; Service d’Anatomie Pathologique, CHU, Montpellier, France; Université Paris-Cité, Service d’Anatomie Pathologique, Hôpital Saint Antoine (AP-HP), Paris, France; Université Paris-Cité, Service d’Anatomie Pathologique, Hôpital Cochin (AP-HP), Paris, France; Université Paris-Cité, Service d’Anatomie Pathologique, ENETS Center of Excellence, Hôpital Beaujon (AP-HP), Clichy, France; Nantes Université, CNRS, UMR6286, US2B, Nantes, France; Université de Reims Champagne-Ardenne, MEDYC, France; Université de Lille, CNRS, Inserm, CHU Lille, UMR9020-U1366 – UPJV, Lille, FranceShow moreShow less
44
days
Broad baseline-variable profiling of visceral conversion in bone-only HR+/HER2 − metastatic breast cancer treated with CDK4/6 inhibitors
Authors
Roberta Scafetta; Raffaella Troiano; Alessandra Guarino; Carla Gullotta; Cristina Fiore; Luisana Sisca; Elena Speziale; Arianna Travisani; Fernando Zannino; Giovanni Miraglia; Marco Donato; Simone Foderaro; Fabio Venuti; Francesco Antonio Vilardi; Valentina Ricozzi; Michele Iuliani; Sonia Simonetti; Silvia Cavaliere; Alessio Cortellini; Annalisa La Cesa; Andrea Di Mattia; Michela Lombardo; Martina Angelone; Andrea Botticelli; Simone Scagnoli; Simona Pisegna; Carmen Criscitiello; Rebecca Pedersini; Caterina Sposetti; Elisa Tiberi; Giuliana D’Auria; Matteo Vergati; Marco Mazzotta; Roberta Caputo; Annarita Verrazzo; Maria Grazia Rossino; Ornella Garrone; Federica Domati; Claudia Piombino; Federica Gatti; Lorena Filomeno; Teresa Arcuri; Federica Puce; Federica Riva; Michela Palleschi; Marianna Sirico; Marta Piras; Luigia Stefania Stucci; Delia De Lisi; Paolo Orsaria; Antonella Grasso; Edy Ippolito; Sara Ramella; Luca Visani; Lorenzo Livi; Stefania Gori; Luigi Rossi; Icro Meattini; Barbara Tagliaferri; Orazio Caffo; Ilaria Portarena; Azzurra Irelli; Elisabetta Cretella; Camillo Porta; Giampaolo Bianchini; Maria Agnese Fabbri; Ugo De Giorgi; Patrizia Vici; Angela Toss; Fiorella Ruatta; Michelino De Laurentiis; Federica Villa; Rossana Berardi; Mauro Minelli; Vittorio Altomare; Claudio Vernieri; Giuseppe Curigliano; Alessandra Chirco; Sara D’Alessandro; Bruno Vincenzi; Giuseppe Tonini; Daniele Santini; Francesco PantanoShow moreShow less
Affiliations
Medical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo 200, Rome 00128, Italy; Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Via Alvaro del Portillo 21, Rome 00128, Italy; Medical Oncology Unit, Santa Rosa Hospital, Department of Oncology and Hematology, Strada Sammartinese snc, Viterbo 01100, Italy; Division of Medical Oncology, “G. Martino” University Hospital, Via Consolare Valeria 1, Messina 98124, Italy; Hospital Pharmacy Fondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo 200, Rome 00128, Italy; Department of Radiological, Oncological and Pathological Sciences, Sapienza University of Rome, Rome, Italy; Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy; Medical Oncology Unit, Azienda Ospedaliero-Universitaria Sant’Andrea, Via di Grottarossa, Rome 1035–1039, Italy; Department of Biomedical Sciences, Humanitas University, via Rita Levi Montalcini 4, Pieve Emanuele, Milan 20072, Italy; Breast Medical Oncology Unit, IRCCS Humanitas Research Hospital, via Manzoni 56, Rozzano, Milan 20089, Italy; Medical Oncology Department, ASST Spedali Civili di Brescia, Brescia, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy; Dana-Farber/Partners CancerCare, Boston, MA, USA; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of Medical Oncology, Università Politecnica delle Marche, AOU delle Marche, Ancona, Italy; Department of Medical Oncology, Medical Oncology Unit, Sandro Pertini Hospital, Rome, Italy; Department of Systems Medicine, 'Tor Vergata' University, Rome, Italy; Department of Breast and Thoracic Oncology, Division of Breast Medical Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Pascale, Naples, Italy; Medical Oncology, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan 20122, Italy; Department of Oncology and Hematology, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy; UOSD Sperimentazioni di fase IV, IRCCS Istituto Nazionale Tumori Regina Elena, Via Elio Chianesi 53, Rome 00144, Italy; Medical Oncology Unit, ICS Maugeri IRCCS, Pavia, Italy; Department of Clinical and Molecular Medicine, Sapienza University of Rome, Policlinico Umberto I, Viale Regina Elena 324, Rome 00161, Italy; Medical Oncology, Breast & GYN Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy; Department of Medical Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy; Interdisciplinary Department of Medicine, University of Bari “A. Moro”, and Division of Medical Oncology, A.O.U. Consorziale Policlinico di Bari, Bari, Italy; Medical Oncology Unit, Santa Chiara Hospital, APSS Trento, Italy; Department of Breast Surgery, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy; Department of Radiation Oncology, Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Rome, Italy; Radiation Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy; Radiation Oncology Unit & Breast Unit, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Florence, Italy; Department of Experimental and Clinical Biomedical Sciences “M. Serio”, University of Florence, Florence, Italy; Medical Oncology Unit, IRCCS Ospedale Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, Verona, Italy; UOC of Oncology, ASL Latina, Formia, Italy; Department of Radiation Oncology (MAASTRO), GROW Research Institute for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, the Netherlands; Center of Medical Science, University of Trento, Trento, Italy; Medical Oncology Unit, Policlinico Universitario Tor Vergata, Rome, Italy; Medical Oncology Unit, Department of Oncology, “Giuseppe Mazzini” Hospital, AUSL 04 Teramo, Teramo 64100, Italy; Medical Oncology Unit, Ospedale di Bolzano, Bolzano, Italy; Università Vita-Salute San Raffaele, Milan, Italy; Department of Experimental Medicine, University of Salento, Lecce, Italy; Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy; Medical Oncology, Oncology Department, ASST Lecco, Lecco 23900, Italy; UOC Oncologia, Azienda Ospedaliera San Giovanni Addolorata, Rome, Italy; European Institute of Oncology, IRCCS, Milan, Italy; ASST Papa Giovanni XXIII, SC Oncologia, Bergamo 24127, Italy; Department of Medical-Surgical Sciences and Biotechnologies, Policlinico Umberto I, Sapienza University of Rome, Rome, ItalyShow moreShow less
100
days
Lenvatinib plus pembrolizumab for the treatment of patients with non-BRAF mutated anaplastic thyroid cancer: A single center, phase 2 clinical trial
Authors
Maria E. Cabanillas; Naifa L. Busaidy; Mark Zafereo; Priyanka C. Iyer; Jennifer R. Wang; Sarah Hamidi; Renata Ferrarotto; Suyu Liu; Gary B. Gunn; Michael Spiotto; Anna Lee; Anastasios Maniakas; Maria Gule-Monroe; Michelle D. Williams; S. Mohsen Hosseini; Victoria E. Banuchi; Mimi I. Hu; Matthew Ning; Ramona DaduShow moreShow less
Affiliations
The University of Texas MD Anderson Cancer Center, Houston, TX, United StatesShow moreShow less
31
days
Diagnostic regulatory pathways are an underrecognized bottleneck in precision oncology clinical trials: Real-world evidence across Europe
Authors
Sarah Hersey; Haydar Celik; Steven Rosen; Christopher Scott; Peter Keeling; Laura Joglekar; Mark LawlerShow moreShow less
Affiliations
Johnston Cancer Research Centre, Queen’s University Belfast, School of Medicine, Dentistry & Biomedical Sciences, Belfast, Ireland, UK; Bristol Myers Squibb, Lawrenceville, NJ, USA; Wyss Institute, Harvard, Boston, MA, USA; Future Medicines Institute, Queen’s University Belfast, Belfast, Ireland, UK; Diaceutics PLC, Belfast, Ireland, UKShow moreShow less
98
days
Older adults with resectable gastric cancer undergoing perioperative chemotherapy or preoperative chemoradiotherapy plus perioperative chemotherapy: A secondary analysis of the AGITG TOPGEAR phase III trial
Authors
Alexander Rühle; Alina Krause; Rachel L. O'Connell; John Simes; Michael Michael; Bernard Mark Smithers; Rebecca K.S. Wong; Karin Haustermans; Nils H. Nicolay; Trevor Leong; Florian LordickShow moreShow less
Affiliations
Department of Radiation Oncology, University of Leipzig Medical Center, Comprehensive Cancer Center Central Germany, Leipzig, Germany; Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, Canada; Department of Medicine II, University of Leipzig Medical Center, Leipzig, Comprehensive Cancer Center Central Germany, Leipzig, Germany; Department of Oncology and University Cancer Center Leipzig (UCCL), University of Leipzig Medical Center, Leipzig, Germany; National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia; Department of Medical Oncology, Peter MacCallum Cancer Centre, and the Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia; Division of Surgery, Princess Alexandra Hospital, University of Queensland, Brisbane, Australia; Department of Radiation Oncology, University Hospitals Leuven, Leuven, Belgium; Department of Radiation Oncology, Peter MacCallum Cancer Centre, and the Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia; Department of Radiation Oncology, University of Toronto, Toronto, CanadaShow moreShow less
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
Client
I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?
CrushSCI
Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.
- Suggested title
- Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment
- Database shortlist
- Environmental Technology & Innovation
SampleLatest 5 valid paper samples from 2026
Average review62 days
Median65 days